Search

Author/Creator Waltz, David

2. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Issue 2 (February 2017)

Authors:
Konstan, Michael W; McKone, Edward F; Moss, Richard B; Marigowda, Gautham; Tian, Simon; Waltz, David; Huang, Xiaohong; Lubarsky, Barry; Rubin, Jaime; Millar, Stefanie J; Pasta, David J; Mayer-Hamblett, Nicole; Goss, Christopher H; Morgan, Wayne; Sawicki, Gregory S
Journal:
Lancet
Issue:
Volume 5:Issue 2(2017)
Page Start:
107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. Issue 2 (17th June 2019)

Authors:
Taylor-Cousar, Jennifer L.; Mall, Marcus A.; Ramsey, Bonnie W.; McKone, Edward F.; Tullis, Elizabeth; Marigowda, Gautham; McKee, Charlotte M.; Waltz, David; Moskowitz, Samuel M.; Savage, Jessica; Xuan, Fengjuan; Rowe, Steven M.
Journal:
ERJ open research
Issue:
Volume 5:Issue 2(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Issue 3 (March 2022)

Authors:
Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jas...
Journal:
Lancet
Issue:
Volume 10:Issue 3(2022)
Page Start:
267
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Issue 7 (July 2017)

Authors:
Ratjen, Felix; Hug, Christopher; Marigowda, Gautham; Tian, Simon; Huang, Xiaohong; Stanojevic, Sanja; Milla, Carlos E; Robinson, Paul D; Waltz, David; Davies, Jane C
Journal:
Lancet
Issue:
Volume 5:Issue 7(2017)
Page Start:
557
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Issue 8 (August 2016)

Authors:
Elborn, J Stuart; Ramsey, Bonnie W; Boyle, Michael P; Konstan, Michael W; Huang, Xiaohong; Marigowda, Gautham; Waltz, David; Wainwright, Claire E
Journal:
Lancet
Issue:
Volume 4:Issue 8(2016)
Page Start:
617
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Issue 10212 (23rd November 2019)

Authors:
Heijerman, Harry G M; McKone, Edward F; Downey, Damian G; Van Braeckel, Eva; Rowe, Steven M; Tullis, Elizabeth; Mall, Marcus A; Welter, John J; Ramsey, Bonnie W; McKee, Charlotte M; Marigowda, Gautham; Moskowitz, Samuel M; Waltz, David; Sosnay, Patrick R; Simard, Christopher; Ahluwalia, Neil; Xua...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1940
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Issue 10212 (23rd November 2019)

Authors:
Heijerman, Harry G M; McKone, Edward F; Downey, Damian G; Van Braeckel, Eva; Rowe, Steven M; Tullis, Elizabeth; Mall, Marcus A; Welter, John J; Ramsey, Bonnie W; McKee, Charlotte M; Marigowda, Gautham; Moskowitz, Samuel M; Waltz, David; Sosnay, Patrick R; Simard, Christopher; Ahluwalia, Neil; Xua...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1940
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Issue 4 (April 2019)

Authors:
McNamara, John J; McColley, Susanna A; Marigowda, Gautham; Liu, Fang; Tian, Simon; Owen, Caroline A; Stiles, David; Li, Chonghua; Waltz, David; Wang, Linda T; Sawicki, Gregory S
Journal:
Lancet
Issue:
Volume 7:Issue 4(2019)
Page Start:
325
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗